Aldeyra Therapeutics, Inc.

ALDX

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Dec 31, 2025

Drug Pipeline

Drug Name	Phase	Indication	Designations
Reproxalap Ophthalmic Solution (0.25%) QID	Phase 3	Dry Eye	-
Vehicle Ophthalmic Solution	Phase 3	Dry Eye	-
Vehicle Opthalmic Solution	Phase 3	Dry Eye	-
ADX-102 1% Topical Dermal Cream (reproxalap)	Phase 3	Sjogren-Larsson Syndrome	-
Placebo Comparator	Phase 3	Dry Eye Disease	-
ADX-2191 (intravitreal methotrexate 0.8%)	Phase 3	Proliferative Vitreoretinopathy	-
Vehicle of ADX-102 Ophthalmic Solution	Phase 3	Non-infectious Anterior Uveitis	-
Reproxalap Ophthalmic Solution (0.5%)	Phase 3	Allergic Conjunctivitis	-
Active topical NS2 1% dermatologic cream	Phase 2	Sjögren-Larsson Syndrome	-
Reproxalap Ophthalmic Solution (0.25%)	Phase 2	Dry Eye Syndromes	-
NS2	Phase 2	Non-infectious Anterior Uveitis	-
ADX-102 Ophthalmic Solution (0.5%)	Phase 2	Dry Eye Syndromes	-
Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID	Phase 2	Dry Eye	-
Placebo	Phase 2	Atopic Asthma	-
ADX-102 Ophthalmic Drops (0.5%)	Phase 2	Conjunctivitis, Allergic	-
ADX-2191	Phase 2	Retinitis Pigmentosa	-
ADX-629	Phase 2	Ethanol Intoxication	-
Reproxalap Ophthalmic Solution (0.1%)	Phase 2	Dry Eye Syndrome	-
ADX-629 (Open-label)	Phase 2	Atopic Dermatitis	-
Xiidra® (5% lifitegrast ophthalmic solution)	Phase 2	Dry Eye	-
NS2 Ophthalmic Drops (0.5%)	Phase 2	Allergic Conjunctivitis	-

Catalyst Timeline

1 upcoming, 0 past

Phase 2Next

Dec 31, 2025ADX-629

Primary completion for ADX-629 trial (NCT06685692) in Alcohol Hepatitis

Regulatory Approvals

ALDX News